On September 9, senior leaders of pharmaceutical company Galderma UK and Ireland and aesthetic product distributor Med-fx met for the official unveiling of their partnership at the Med-fx headquarters in Witham, Essex.
Pharmaceutical company Galderma (UK) Limited has confirmed that aesthetic and skincare product supplier Med-fx Ltd will become the company’s preferred distributor, subject to contract, for its aesthetics portfolio.
Two of the industry’s leading companies could become one if a multi-million dollar bid by Galderma to acquire Q-Med goes ahead. In a joint venture between L’Oreal and Nestle. Galderma, the makers of Azzalure®, launched a reported $970 million bid for the Swedish manufacturer of Restylane® at the end of 2010.
The Food and Drug Administration (FDA) has approved Restylane Refyne and Restylane Defyne dermal fillers from Galderma for the treatment of nasolabial folds.
International pharmaceutical company Galderma has launched a new hologram on all packaging across the entire Restylane portfolio of Non-Animal Stabilised HA (NASHA) and Optimal Balance Technology (OBT) products, as well as the Skinboosters range to provide practitioners with further assurance that the products are original.
The results of two studies conducted by pharmaceutical company Galderma (UK) Limited have demonstrated high patient satisfaction for the use of Azzalure (AbobotulinumtoxinA), its botulinum toxin type A product, in the glabellar complex.
Global pharmaceutical company Galderma has appointed Kendrick PR and Mantlepiece PR as its new UK representatives.
Pharmaceutical company Galderma invited guests to a celebratory breakfast in the Duncan Room at the Charlotte Street Hotel for the 20th anniversary of Restylane.
Pharmaceutical company Galderma has released the results of its two phase III studies for its liquid formulation of botulinumtoxinA (relabotulinumtoxinA).
Know our NASHAs from our OBTs to create a personalised signature look with Restylane hyaluronic acid fillers